More Articles

Generics losing out to brand-name drugs in Croatia Generics/Research | Posted 28/11/2014

A combination of weak national guidelines and powerful marketing by the pharmaceutical industry has led to a rise in brand-name over generics prescriptions for psychopharmaceuticals in Croatia.

FDA to carry out survey into affect of generics shape, colour, size Guidelines | Posted 28/11/2014

The US Food and Drug Administration (FDA) wants to understand how patients’ perceptions of medications change when pharmacies switch from brand-name to generic drugs or between the same generics ma...

Developments in the US over state biosimilars substitution rules Policies & Legislation | Posted 28/11/2014

The US Food and Drug Administration (FDA) is still to finalize guidelines regarding biosimilars and has yet to approve a biosimilar. However, despite this fact, many US states are considering, or h...

FDA withdraws automatic substitution of two methylphenidate generics Generics/News | Posted 28/11/2014

The US Food and Drug Administration (FDA) announced on 13 November 2014 that it had withdrawn the bioequivalence rating for two generic versions of Janssen Pharmaceutica’s attention deficit hyperac...

Amgen expands biosimilars programme Biosimilars/News | Posted 28/11/2014

Biologicals major Amgen is expanding its biosimilars portfolio to include nine different molecules.

Actavis buys Allergan and joins pharma top 10 Pharma News | Posted 28/11/2014

On 17 November 2014, US generics maker Actavis announced that the company had made a deal to acquire botox-maker Allergan for US$66 billion.

Extrapolation of indications in biosimilars: filgrastim Biosimilars/Research | Posted 21/11/2014

Extrapolation* of indications for biosimilars is a contentious issue and has been met with concern by physicians. Members of the European Medicines Agency's (EMA) Biosimilar Medicinal Products Work...

More discussion over WHO biological qualifier Biosimilars/General | Posted 21/11/2014

The World Health Organization recently held its 59th Consultation on International Nonproprietary Names (INN) for Pharmaceutical Substances. At the meeting the issue of naming of biologicals includ...